Adaptimmune Therapeutics (ADAP) Stock Forecast & Price Target

$0.59 0.00 (0.00%)

(As of 11/15/2024 ET)

Adaptimmune Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 4 Analyst Ratings

Sell
0

Hold
0

Buy
4

Based on 4 Wall Street analysts who have issued ratings for Adaptimmune Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 4 analysts, 4 have given a buy rating for ADAP.

Consensus Price Target

$3.16
439.12% Upside

According to the 4 analysts' twelve-month price targets for Adaptimmune Therapeutics, the average price target is $3.16. The highest price target for ADAP is $3.50, while the lowest price target for ADAP is $3.00. The average price target represents a forecasted upside of 439.12% from the current price of $0.59.

ADAP Analyst Ratings Over Time

Type	Current Forecast 11/17/23 to 11/16/24	1 Month Ago 10/18/23 to 10/17/24	3 Months Ago 8/19/23 to 8/18/24	1 Year Ago 11/17/22 to 11/17/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$3.16	$3.38	$3.38	$4.65
Forecasted Upside	439.12% Upside	302.06% Upside	213.27% Upside	870.77% Upside
Consensus Rating	Buy	Buy	Buy	Moderate Buy

the biggest gold rally of our lifetimes? (Ad)

Commodities expert, Geof Smith, insists that the supercycle on gold is just getting warmed up. In fact, even though gold looks like this since he initially called a major bull run 11 months ago… He’s still predicting it will be the TOP trade of 2025. His free eBook explains why You see, the last time gold launched into a supercycle like this it surged 536% The time before that was over 1,000%... That’s why Geof released this urgent guide to help you. Most people think they’ve missed out, but he thinks we’re at the very beginning of what could be the largest gold rally of our lifetimes. But, believe it or not, Geof doesn’t think you should just buy and hold precious metals. He’ll share more about his approach inside the eBook and it might surprise you.

Tap here to read it

ADAP Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ADAP Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Adaptimmune Therapeutics Stock vs. The Competition

Type	Adaptimmune Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	439.12% Upside	28,534.17% Upside	9.92% Upside
News Sentiment Rating	Neutral News See Recent ADAP News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/15/2024	Guggenheim 3 of 5 stars		Lower Target	Buy ➝ Buy	$4.00 ➝ $3.00	+409.33%
11/14/2024	HC Wainwright 2 of 5 stars	A. He Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$4.00 ➝ $3.50	+482.16%
5/30/2024	Scotiabank 5 of 5 stars	G. Farmer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$3.15	+211.88%
5/17/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$9.00 ➝ $3.00	+150.00%
8/10/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Underweight ➝ Underweight	$2.00 ➝ $1.00	+17.65%
4/17/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$10.00	+606.71%
3/24/2023	Bryan, Garnier & Co Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$3.60	+230.27%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 03:24 AM ET.

ADAP Forecast - Frequently Asked Questions

: According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Adaptimmune Therapeutics is $3.16, with a high forecast of $3.50 and a low forecast of $3.00.
: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ADAP shares.
: According to analysts, Adaptimmune Therapeutics's stock has a predicted upside of 439.12% based on their 12-month stock forecasts.
: Adaptimmune Therapeutics has been rated by research analysts at Guggenheim, and HC Wainwright in the past 90 days.
: Analysts like Adaptimmune Therapeutics more than other "medical" companies. The consensus rating for Adaptimmune Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ADAP compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out? (Ad)

Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?

Click Here For Your Free Guide

This page (NASDAQ:ADAP) was last updated on 11/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adaptimmune Therapeutics (ADAP) Stock Forecast & Price Target